Lantheus Holdings, Inc. (NASDAQ:LNTH) Q2 2022 Earnings Conference Call August 4, 2022 8:08 AM ET

Company Participants

Mark Kinarney - Senior Director, Investor Relations

Mary Heino - President and Chief Executive Officer

Robert Marshall - Chief Financial Officer and Treasurer

Paul Blanchfield - Chief Commercial Officer

Conference Call Participants

Richard Newitter - Truist Company

Zach Weiner - Jefferies

Roanna Ruiz - SVB Securities

Larry Solow - CJS Securities

Anthony Petrone - Mizuho Securities

Operator

Good morning, ladies and gentlemen. Welcome to the Lantheus Second Quarter 2022 Conference Call. This is your operator for today's call. [Operator Instructions] I'll now turn the call over to your host for today, Mark Kinarney, Vice President of Investor Relations. Please go ahead.

Mark Kinarney

Thank you, and good morning. Welcome to Lantheus' Second Quarter 2022 Conference Call. With me on today's call are Mary Anne Heino, our President and CEO; Bob Marshall, our Chief Financial Officer; and Paul Blanchfield, our Chief Operating Officer. Mary Anne will begin the call with introductory remarks and then turn the call over to Paul to provide an operational update. Bob will cover our financial results and updated guidance. Mary Anne will provide closing remarks, and then we will open the call for Q&A.

This morning, we issued a press release, which was furnished to the Securities and Exchange Commission under Form 8-K, reporting our second quarter 2022 results. You can find the release in the Investors section of our website at lantheus.com. For those of you not on the webcast, you can find the slide presentation in the Investors section of our website under the Presentations tab.

Before I get started, I would like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements due to a variety of risks and uncertainties. Please note that we assume no obligation to update these forward-looking statements, except as required by applicable law, even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties. Also, discussions during the call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included on the Investors section of our website. With that, it's my pleasure to now turn the call over to Mary Anne.

Mary Heino

Thank you, Mark, and good morning to everyone joining us. We had another outstanding quarter as we continue to execute on our strategy to accelerate growth, diversify our portfolio and position Lantheus as a category leader in the markets in which we compete. I'm particularly pleased to share that, for the second quarter in a row, we reported record revenue, up 121% year-over-year, led by PYLARIFY growth in our radiopharmaceutical oncology category. Having launched PYLARIFY just over 1 year ago, we are delighted with the impact PSMA-targeted PET imaging is making on the U.S. prostate cancer community. In fact, at our inaugural Investor Day in May, Dr. E. David Crawford, an internationally renowned urologist at the University of California San Diego, highlighted that he believes PET PSMA imaging is one of the most important steps forward he has seen in prostate cancer in the last few decades. We believe that endorsements from experts in the field such as Dr. Crawford's, along with inclusion in the guidelines for both the National Comprehensive Cancer Network, or NCCN, and the Society of Nuclear Medicine and Medical Imaging or SNMMI, speak to the importance of PSMA-targeted PET imaging for the U.S. prostate cancer community.